[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transgender-persons\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transgender-persons":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,38,69,92,117,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100510508","research-participation-with-transgender-and-gender-diverse-youth-100510508",false,"NCT05927350","Research Participation With Transgender and Gender-Diverse Youth","Inclusion Criteria:\n\n* Gender identity different then sex assigned at birth\n* Between the ages 15-21 years\n\nExclusion Criteria:\n\n* Gender identity the same as their sex assigned at birth\n* Younger than 15 years of age, and older than 21 years of age","ALL","15 Years","21 Years",{"count":19,"type":20},250,"ESTIMATED","OBSERVATIONAL","Research has historically excluded the participation of transgender and gender-diverse people. The purpose of this research study is to find out about what goes into a transgender and gender-diverse youth's decision to participate in research. The results of this study will be used to improve access to research for transgender and gender-diverse youth and therefore, improve the representation of transgender and gender-diverse youth as research participants in research.",[24],"Transgender Persons","RECRUITING","2026-02-17",{"date":28,"type":29},"2026-02-20","ACTUAL",{"date":31,"type":29},"2025-01-29",{"date":33,"type":20},"2026-06",{"name":35,"class":36},"Virginia Commonwealth University","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":15,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":37},"100580070","phase-4-investigating-gender-and-sex-differences-in-immune-responses-through-vaccination-of-transgender-and-cisgender-persons-100580070","NCT06832514","Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons","An Investigator-initiated, Single-center Academic Study in Healthy Transgender and Cisgender Persons Aged Between 18 and 50 Years to Investigate Gender and Sex Differences in Immune Responses to Meningococcal Serogroup B Vaccination","Vaxxygender","Inclusion Criteria:\n\n1. Written signed informed consent form (ICF) obtained before any study-related activities.\n2. Participants aged between, and including, 18 and 50 years of age at the time of signing the ICF which equals with the time of the first study intervention.\n3. Participants who are considered to be in good general health as determined by the investigator by medical evaluation including medical history andphysical examination at enrollment.\n4. Participants with a BMI within the range 18.5 to 35 kg\u002Fm2 inclusive at screening.\n5. POCBP (18-50 years of age) who are not pregnant or breastfeeding or planning to become pregnant during the clinical study.\n6. Transgender persons need to be under stable gender-affirming hormone therapy (GAHT) for at least 6 months. Compliance needs to be documented by hormonal lab tests.\n7. POCBP must have a negative urine pregnancy test at each vaccination visit (Visit 1 and Visit 5) Refer to Section 8.6.5 for Pregnancy Testing.\n8. Participants who are willing and able to comply with the study procedures and are capable to comply with the requirements of the protocol (e.g. return for follow-up visits) as determined by the investigator.\n\nExclusion Criteria:\n\n1. Current or previous, confirmed or suspected disease caused by N. meningitidis and N. gonnorrhoea.\n2. Household contact with and\u002For intimate exposure (e.g. sexual or saliva contact) to an individual with laboratory confirmed N. meningitidis infection during life.\n3. Transgender persons in a diagnostic phase (no hormonal intervention) or undergoing treatment based on the suppression of endogenic hormones (e.g. gonadotropin releasing hormone analogues).\n4. Current or previous infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV) as determined by anamnesis and medical history.\n5. Past or current confirmed or suspected immune-suppressive or immune-deficient condition, at the discretion of the investigator, including but not limited to blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders, lupus erythematosus and associated conditions or disorders (e.g. rheumatoid arthritis, scleroderma) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).\n6. History of confirmed hypersensitivity, anaphylaxis and\u002For other severe allergic reactions (e.g., generalized urticaria, angioedema, bronchospasm) to any component of the study vaccine or excipients (sodium chloride, histidine, sucrose, kanamycin and water for injection), medical products, or medical equipment whose use is foreseen in this study, as determined by the investigator.\n7. Clinical conditions representing a contraindication for IM administration and blood draws, as judged by the investigator, e.g. thrombocytopenia or history of bleeding disorder (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties.\n8. History of asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen.\n9. Active malignancy or malignancy within the past 5 years that, in the opinion of the investigator, may affect immune response or participant safety - except for localized and fully treated cancers not requiring long-term therapy such as chemotherapy or radiotherapy (e.g. completely resected basal cell carcinoma, cervical intraepithelial neoplasia, melanoma in situ, early-stage thyroid cancer), based on the investigator's clinical judgement.\n10. History of idiopathic urticaria within the past year.\n11. Currently pregnant, breast-feeding or planning to become pregnant. Cisgender women with permanent infertility due to an alternate medical cause (e.g. documented bilateral oophorectomy, androgen insensitivity, gonadal dysgenesis) are excluded to participate. For individuals with permanent infertility due to an alternate medical cause other than the above, investigator discretion should be applied to determining study entry. Additionally, cisgender women in a postmenopausal state, defined as no menses for 12 months without an alternative medical cause are also excluded to participate. Refer to\n12. Any other clinical condition that, in the opinion of the investigator, could compromise the participant's safety and\u002For compliance with the study protocol (e.g. current or recent (\\\u003C 1 years ago) heavy smoking (\\> 20 cigarettes per day) or daily heavy vaping (equivalent to 20 cigarettes), drug- or alcohol (\\> 15 units for cisgender men and transgender women or \\> 10 units or cisgender women and transgender men per week) abuse\u002Faddiction.\n13. Behavioral or cognitive impairment, unstable psychiatric conditions (e.g. forced admission, suicidal thoughts in the last two year) or other psychiatric disease that, in the opinion of the investigator, may interfere with study compliance, as well as with the subject's ability and\u002For safety to participate in the study. Stable psychiatric conditions (e.g. under-controlled depression) will be evaluated based on the investigators judgement.\n14. Donation of blood or blood products within 90 days prior to the first vaccination visit (Visit 1) until Day 56 (Visit 9).\n15. Previous vaccination against any group B meningococcal vaccine (Bexsero®, Trumenba®) at any time prior to informed consent.\n16. Prior receipt of a live-attenuated vaccine in the 28 days prior to administration of the 4CMenB vaccine, within 14 days for subunit or inactivated vaccines or planning to receive a vaccine in between the first and second vaccine administration, as well as 28 days following administration of the second 4CMenB vaccine dose.\n17. Currently participating in another clinical study, or planning to participate in another study during the study period, or administration of any investigational drug or medical device in the 28 days prior to study vaccination.\n18. Prior receipt of blood, blood-derived products or immunoglobulins in the 6 months prior to administration of the study vaccine, or planning to receive such product during the study period.\n19. Chronic administration (defined as 14 consecutive days in total) of immunosuppressants (e.g. corticosteroids (PO\u002FIV\u002FIM) or other immune-modifying drugs (e.g. antineoplastic agents, radiotherapy) during the period starting 90 days prior to vaccination or planned administration during the study (excluding topical, inhaled and intranasal preparations and intra-articular injections). For corticosteroids, this will mean prednisone ≥ 20 mg\u002Fday, or equivalent.\n20. POCBP (cisgender women and transgender men) who use the following contraceptive methods will not be included in the study\n\n    * Oral, injectable, intravaginal (i.e. intravaginal ring) or transdermal combined (oestrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation.\n    * Oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation.\n21. Current anti-tuberculosis prophylaxis or therapy.\n\n25\\. Participants with a history of any medical conditions that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the participants when participating in the study.",true,"18 Years","50 Years",{"count":19,"type":20},"INTERVENTIONAL",[52],"PHASE4","Sexual differences are a well-established source of biological variation in immune system functioning, with men often displaying lower adaptive immune responses (e.g. antibody production) to infections and vaccinations compared to women. The impact of sex and gender on immune responses and immune functioning warrants more in-depth investigation. This study is an investigator-initiated project aimed at prospectively assessing the immune response towards a vaccine in transgender and cisgender individuals. Transgender individuals retain their chromosomal sex while undergoing a significant hormonal shift that aligns with their experienced gender. Immune responses induced by the four-component meningococcal serogroup B (4CMenB; Bexsero®) vaccine will be evaluated in transgender individuals and compared with responses observed in cisgender individuals. Both humoral and cellular immune responses induced by two doses of the 4CMenB vaccine will be quantified and analysed. This approach is expected to provide new insights into the effects of gender and sex differences on innate and adaptive immune responses.",[55,24,56,57],"Meningococcal Meningitis, Serogroup B","Sex Differences in Immune Response","Vaccination",[59],"Gender","2026-01-15",{"date":62,"type":29},"2026-01-20",{"date":64,"type":29},"2025-01-31",{"date":66,"type":20},"2026-12-31",{"name":68,"class":36},"University Ghent",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":37},"100604392","perception-of-pain-during-gender-affirming-hormone-therapy-100604392","NCT07148921","Perception of Pain During Gender Affirming Hormone Therapy","Changes in Pain and Perception Thresholds Due to Gender Affirming Hormone Therapy: a Prospective Exploratory Cohort Study","Inclusion Criteria:\n\n* ≥ 18 years of age\n* Assigned female at birth (AFAB)\n* Diagnosed gender identity disorder\u002Fgender dysphoria and planned therapy with testosterone OR\n* ≥ 18 years of age\n* Assigned male at birth (AMAB)\n* Diagnosed gender identity disorder\u002F gender dysphoria and planned therapy with estradiol\n\nExclusion Criteria:\n\n* Any sex hormone intake during the last 6 months\n* Acute or chronic pain\n* Polyneuropathy\n* Diagnosis of alcohol or drug addiction\n* BMI under 18 or over 35\n* Pregnancy\n* Breastfeeding\n* Pharmacological analgesic therapy within the previous 7 days before each examination\n* History of significant trauma or surgery to the hands with residual neurological deficit or pain.",{"count":77,"type":20},40,"It is known from the literature that women and men differ in their perception of pain. Why this is the case has not been conclusively clarified. Sex hormones could have a significant influence on this. The study team suspects that the classic hormone status of women is responsible for the lower pain threshold compared to men.\n\nPeople undergoing gender affirming therapy receive biologically opposite-sex hormones in order to adapt their external appearance as well as their voice, emotional life etc. to the desired gender. The aim of this study is to longitudinally record whether the intake of opposite-sex sex hormones leads to a change in pain and perception thresholds in this patient collective. To this end, potential study participants will be informed about the study and asked whether they would like to participate before the start of hormone therapy during their first visit to the transgender outpatient clinic.\n\nIf consent is given, a questionnaire on mental health (PHQ 9), a blood sample to determine the hormone status and the first QST (quantitative sensory testing) measurement are then carried out. The second measurement with blood sampling takes place 3-4 weeks after the first measurement. The 3rd and 4th measurements with blood sampling are taken 3 and 6 months respectively after the first measurement. The PHQ 9 is measured again at the time of the last measurement. Study participation ends after a total of 6 months. The blood samples, the PHQ 9 and the QST measurements have no influence on the treatment of the study participants.",[24,80,81,82],"Pain Threshold","Perception of Pain","Sex Hormones","2025-08-22",{"date":85,"type":29},"2025-08-29",{"date":87,"type":29},"2024-12-01",{"date":89,"type":20},"2026-03",{"name":91,"class":36},"Medical University of Vienna",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":46,"sex":15,"minAge":47,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":50,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":37},"100529732","transhealthguide-transforming-health-for-gender-diverse-young-adults-100529732","NCT06177600","TransHealthGUIDE: Transforming Health for Gender-Diverse Young Adults","TransHealthGUIDE: Transforming Health for Gender-Diverse Young Adults Using Interventions to Drive Equity","Inclusion Criteria:\n\n* Gender diverse individuals aged 18-29 years residing in California, Oregon, Illinois, Maryland, District of Columbia, Vermont, Connecticut, Massachusetts, Michigan, New Jersey, or New York\n* Caregivers of gender diverse individuals aged 18-29 years residing in California, Oregon, Illinois, Maryland, District of Columbia, Vermont, Connecticut, Massachusetts, Michigan, New Jersey, or New York\n\nExclusion Criteria:\n\n* Inability to speak, read, and write English\n* Lack of device with Internet access\n* Current residence in location other than California, Oregon, Illinois, Maryland, District of Columbia, Vermont, Connecticut, Massachusetts, Michigan, New Jersey, or New York","29 Years",{"count":101,"type":20},500,[103],"NA","This is a randomized controlled trial to test the effectiveness of an interactive educational app-based digital intervention that provides knowledge and support to transgender and gender-diverse (TGD) young adults ages 18-29 years and their caregivers. The goal of the study is to examine the effects of exposure to the app on TGD young adult mental health outcomes.\n\nParticipants will be randomized to an Immediate Arm (access to a digital platform, plus usual care) or a Deferred Arm (usual care; access to the digital platform at 6 mo). Usual care consists of access to published resources and community support organizations, if available. The list of resources will include contact information for a suicide prevention hotline. For each Arm, the intervention period will last 6 months, followed by 6 months of observation, during which access to the intervention is maintained. Assessments will be performed at baseline, 3, 6, and 12 months to document changes in mental health outcomes, and the two groups will be compared.\n\nThe investigators plan to enroll 500 TGD young adults and their caregivers, with at least 50% (250 participants) to identify as Black, Indigenous, People of Color (BIPOC) and 50% (125 TGD young adults, 125 caregivers) to be young adult-caregiver dyads.\n\nOngoing process reassessments will be performed to maximize effectiveness of the intervention, including focus groups and in-depth interviews with TGD young adults, caregivers, and providers, as well as analysis of data collected through the digital platform and participant surveys. Investigators will account for sociodemographic characteristics such as race and ethnicity, age, gender identity, education status, existing mental health conditions, and history of suicidal ideation or attempt. Data will be analyzed across racial minority groups to ensure that the intervention is effective for all racial minorities; if there are discrepancies in effectiveness, additional mixed methods evaluation will be performed to identify and address potential causes.",[24,106,107],"Health Services for Transgender Persons","Gender Identity","2025-08-15",{"date":110,"type":29},"2025-08-20",{"date":112,"type":29},"2025-04-23",{"date":114,"type":20},"2026-08-31",{"name":116,"class":36},"Boston Children's Hospital",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":46,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":138,"locationsCount":37},"100581796","cohort-study-on-factors-associated-with-the-evolution-of-quality-of-life-among-transgender-individuals-in-the-french-population-100581796","NCT06854965","Cohort Study on Factors Associated with the Evolution of Quality of Life Among Transgender Individuals in the French Population","TRANSPOSE","Inclusion Criteria:\n\n* Person identifying themselves as trans\n* Person of legal age (≥ 18 years)\n* Person living in France\n* Person who has not expressed any opposition after receiving full information about the protocol\n* Person who understands and speaks French, or who is an allophone speaking English, Spanish or Portuguese\n\nExclusion Criteria:\n\n* People who do not understand or speak French, English, Spanish or Portuguese.\n* Person under guardianship or curatorship, under legal protection or under safeguard of justice\n* Anyone who has expressed their opposition after receiving full information about the protocol.",{"count":125,"type":20},1500,"This research focuses on identifying medical, social, and healthcare journey determinants associated with the evolution of quality of life in the transgender population at 12 months. To address the research question, it is planned to include 1,500 transgender individuals, among those attending healthcare professionals or associations in the French territory who have agreed to take on the role of investigators (professionals in healthcare or designated individuals within an association).",[24],[129,130],"Transgender","Quality of Life (QoL)","NOT_YET_RECRUITING","2025-02-28",{"date":134,"type":29},"2025-03-03",{"date":132,"type":20},{"date":137,"type":20},"2027-02-28",{"name":139,"class":36},"CNGE Conseil",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":37},"100553566","new-onset-chronic-pelvic-pain-in-transgender-people-using-testosterone-therapy-an-exploratory-qualitative-study-100553566","NCT06487754","New-onset Chronic Pelvic Pain in Transgender People Using Testosterone Therapy: an Exploratory Qualitative Study.","Inclusion Criteria:\n\n* Being a trans masculine individual\n* Taking a gender affirming hormonal therapy (GAHT)\n* living close to Grenoble\n* having pelvic pain that appeared or were modified after taking GAHT\n\nExclusion Criteria:\n\n* Subject under guardianship or subject deprived of liberty Refusal of voice recording",{"count":147,"type":20},15,"This descriptive qualitative study aim to describe the characteristics of pelvic pain in transgender (trans) individuals using testosterone therapy and the impact on their quality of life. This study also aim to understand the levers and obstacles to consulting a health care professional.",[24,150,151,152],"Pelvic Pain","Testosterone","Gender-Affirming Care","2024-12-12",{"date":155,"type":29},"2024-12-17",{"date":157,"type":29},"2024-09-27",{"date":159,"type":20},"2025-12",{"name":161,"class":36},"University Hospital, Grenoble"]